Investigators looked at adherence in patients who switched from reference infliximab during treatment for rheumatologic and gastrointestinal treatment.
In a study of use of infliximab biosimilars among patients with gastrointestinal and rheumatologic conditions, investigators found high adherence.
The retrospective study, presented at the American College of Rheumatology (ACR) annual meeting, involved 533 patients in the IBM MarketScan commercial insurance database who were treated with infliximab from 2014 to 2018. Investigators characterized those who initiated use of infliximab biosimilars after treatment with the reference product or no prior infliximab treatment.
Patients were divided according to never having used infliximab reference product, early switchers with less than 2 years of reference product use, and late switchers with greater than 2 years of reference product use.
Investigators said 41.6% to 47.4% of patients had inflammatory bowel disease and 34.2% to 48.7% had rheumatoid arthritis. Psoriasis patients accounted for 8.8% to 14.2% of the population.
Roughly half of patients were highly adherent to infliximab biosimilars at 12 months of treatment with these alternative agents. Among those with ≥ 12 months of follow-up care, 53.6% of naïve users, 44.3% of early switchers, and 56.1% of late switchers remained highly adherent at 12 months.
High adherence among patients with at least 18 months of follow-up amounted to 59.3% for naïve infliximab biosimilar users, 50% for early switchers, and 40.7% for late switchers.
Investigators found that there was no significant difference in adherence among those who initiated biosimilar infliximab.
Investigators divided comorbidity rates according to patient type. Among infliximab naïve users, 14.3% had diabetes; 42.9%, hypertension; 17.3%, depression; chronic obstructive pulmonary disease, 19.4%; and cancer, 11.2%.
The respective percentages for early switchers were 17.5%, 37.7%, 21.1%, 7%, and 3.5%; and for late switchers, 15.9%, 38.1%, 10.6%, 15.9%, and 11.5%.
The adjusted odds ratio for high adherence among naïve infliximab biosimilar users was 1.68 (P = .26); and for early switchers, 0.70 (P = .35), meaning the former group was far more likely to adhere to infliximab biosimilar than the latter group.
Reference
Sarvesh S, Alanaeme JC, Curtis JR, Yun H. Utilization and adherence among infliximab biosimilar initiators in a U.S. national commercial insurance database. Presented at: ACR Convergence 2020; November 5-9, 2020. Poster 0555.
FDA and Industry Experts Unpack Biosimilar Device Requirements
October 23rd 2024At the GRx+Biosims 2024 conference, a panel of industry experts and FDA officials discussed evolving device requirements for biosimilars and interchangeable biosimilars, highlighting new approaches to comparative use human factors studies, regulatory challenges, and alternative validation methods.
Breaking Barriers in Osteoporosis Care: New Denosumab Biosimilars Wyost, Jubbonti Approved
June 16th 2024In this episode, The Center for Biosimilars® delves into the FDA approval of the first denosumab biosimilars, Wyost and Jubbonti (denosumab-bbdz), and discuss their potential to revolutionize osteoporosis treatment with expert insights from 2 rheumatologists.
Unifying Standards: The Need for Streamlined Biosimilar Development
October 22nd 2024At the 2024 GRx+Biosims conference, industry leaders and regulatory experts underscored the urgency of unifying global standards and simplifying the biosimilar development process, sharing insights on recent advancements and the necessity for greater collaboration between manufacturers and regulatory agencies.
Biosimilars Gastroenterology Roundup for May 2024—Podcast Edition
June 2nd 2024On this episode of Not So Different, we review the biggest gastroenterology biosimilar stories from May 2024, covering new data from conferences and journals on infliximab and adalimumab products that demonstrate positive clinical results and confirm the safety of these biosimilars, as well as the feasibility of switching to them.
Phase 3 Study Reports Similar Efficacy Between SB17, Stelara in Psoriasis
October 19th 2024A phase 3, 28-week comparative clinical trial in patients with moderate to severe plaque psoriasis confirmed similarity of the proposed ustekinumab biosimilar SB17 (Samsung Bioepis) to the reference product (Stelara) in efficacy, safety, pharmacokinetics, and immunogenicity.
Eye on Pharma: Aflibercept Legal Drama; PBM, Humira Biosimilars; Denosumab Regulatory Review
October 15th 2024Regeneron appeals legal decision after judge refuses to block an aflibercept biosimilar; Prime Therapeutics, a pharmacy benefit manager (PBM), becomes the latest to offer biosimilars referencing Humira (adalimumab) at a low cost; the FDA and European Medicines Agency accept a denosumab biosimilar candidate for review.